US awards $1.6 billion to Novavax for COVID-19 vaccine
Washington (AFP) - The US on Tuesday announced it was providing $1.6 billion in funding for the development and manufacture of a COVID-19 vaccine candidate produced by biotech firm Novavax, the largest amount awarded under Operation Warp Speed.Separately, the US also said it was providing $450 million to Regeneron for its experimental COVID-19 treatment and prophylaxis, a combination of two antibodies.Under the terms of its agreement with the Department of Health and Human Services (HHS) and Department of Defense, Novavax agrees to deliver 100 million doses of its vaccine, potentially by the e...
Regeneron COVID-19 treatment enters final stage trials
Washington (AFP) - The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19.The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus' "spike protein" which it uses to invade human cells. The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus -- for example through a person in their household.This trial, run jointly with the US National Institute of Allergy...
Regeneron, Sanofi Drop After-Hours as Covid-19 Vaccine Trial Halted
Investing.com -By Christiana SciaudoneInvesting.com -- Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)fell 2.6% and Sanofi (PA:SASY)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.A trial of patients who received a dose of 800 mg of Kevz...
Moderna CEO Stephane Bancel & Regeneron CEO Leonard Schleifer on a Coronavirus vaccine
CNBC’s Meg Tirrell interviews Moderna CEO Stephane Bancel & Regeneron CEO And Founder Leonard Schleifer From CNBC’s Healthy Returns Summit TodayQ1 2020 hedge fund letters, conferences and moreAnd Leonard SchleiferFollowing is the unofficial transcript of a CNBC interview with Moderna CEO Stephane Banceland Regeneron CEO and Founder Leonard Schleiferlive from CNBC’s Healthy Returns virtual summit on Tuesday, May 12th.TYLER MATHISEN: Our next discussion is with the leader of two companies that are on the forefront of trying to develop both treatments and vaccines for COVID-19. I'm going to ask n...